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their lateral aggregation, thick fibrin fibers are 
crosslinked in a reaction catalyzed by thrombin­
­activated factor XIII.1 Fibrin, together with plate­
lets and red blood cells, provide structural in­
tegrity to the hemostatic plug under physiolog­
ical conditions and to the growing thrombus in 
thrombotic disorders.
The final fibrin clot has a highly heterogeneous 
structure, determined by genetic and, to a much 
larger extent, environmental factors, which re­
sults in a large interindividual variability of clot 
architecture, thickness of fibers, and their branch­
ing.2 Lower fibrinogen concentrations are known 
to result in the formation of thicker fibrin fibers 
creating looser meshwork which is more suscep­
tible to fibrinolysis and mechanical fragmenta­
tion, eventually leading to an increased risk of 
bleeding. On the other hand, irregular abnormal 
Fibrinogen structure Fibrinogen is a 340 kDa pro­
tein synthesized in the liver.1 Its normal con­
centration in blood plasma is in the range of 
1.5 to 4.0 g/l. The half ­life of circulating fibrin­
ogen is about 3 to 4 days. The fibrinogen mole­
cule is a hexamer, made up of 3 pairs of homolo­
gous Aα, Bβ, and γ polypeptide chains connect­
ed by disulfide bridges that form a central E re­
gion composed by the N ­terminal portions of 
all 6 chains and 2 terminal D regions containing 
the C ­terminal fragments of the Bβ and γ chains.1 
The C ­terminal fragments of the Aα chains form 
globular structures located near the central E re­
gion.1 After cleavage of fibrinopeptides A and 
B mediated by thrombin, fibrin monomers are 
formed, which polymerize through the interac­
tion of the D region with the E regions of subse­
quent monomers to form protofibrils and through 
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ABSTRACT
Congenital qualitative and quantitative fibrinogen disorders represent heterogeneous rare abnormalities 
caused by mutations in one of the 3 genes encoding individual fibrinogen polypeptide chains, located on 
chromosome 4q28. It is estimated that congenital fibrinogen disorder accounts for 8% of rare coagulation 
factor deficiencies. Most of congenital fibrinogen disorders are suspected in individuals with bleeding 
tendency or coincidentally discovered, for instance prior to surgery. Fibrinogen disorders could be also 
found in patients with thrombotic events, impaired wound healing, and recurrent spontaneous abortions. 
Afibrinogenemia manifests as mild to severe bleeding, while hypofibrinogenemia is often asymptomatic. 
Dysfibrinogenemia, a qualitative fibrinogen disorder, is associated with bleeding, thrombosis, or with no 
symptoms. Recent recommendations issued by the International Society on Thrombosis and Haemostasis 
in 2018 do not encourage routine evaluation of thrombin time or other coagulation tests in patients with 
suspected congenital fibrinogen disorders, highlighting the value of fibrinogen antigen measurement 
and genetic analysis, added to the key finding, that is, reduced fibrinogen concentration determined 
with a coagulometric assay. The current review summarizes practical issues in diagnostic work up and 
clinical management of patients with afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and 
hypodysfibrinogenemia from a perspective of internists who may encounter patients with reduced 
fibrinogen concentration in everyday practice. Despite the fact that hematologists are in front line for 
the management of patients with bleeding tendency, internists should be aware of the clinical and labora-
tory findings in patients with inherited fibrinogen disorders including the risk of thromboembolism and 
management prior to invasive procedures.
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FGA and other affecting Arg301 in exon 8 of FGG. 
The mechanisms underlying clinical manifesta­
tions observed in qualitative congenital fibrin­
ogen disorders involve abnormal formation of 
a fibrin clot associated with disturbed release 
of fibrinopeptides, delayed fibrin polymeriza­
tion or defective cross ­linking.4,8,9 A single muta­
tion altering a fibrinogen chain may result in sig­
nificant changes in the tertiary and quaternary 
structure of the protein causing all of the above 
disorders.4,8,9 To date, about 30 different muta­
tions causing hypodysfibrinogenemia have been 
identified (10 in the FGA gene, 5 in the FGB gene, 
and 15 in the FGG gene). Most of these fibrinogen 
mutations were inherited in an autosomal dom­
inant manner.10 Combined heterozygosity was 
found in additional 7 patients with hypodysfi­
brinogenemia.10 In patients with hypodysfibrin­
ogenemia, the hypofibrinogenemic phenotype re­
sults from mutation affecting synthesis, assembly, 
and secretion or leading to an increased fibrino­
gen clearance, while the dysfibrinogenemic phe­
notype results from impaired fibrin polymeriza­
tion and abnormal binding of calcium ions or tis­
sue plasminogen activator.10
The first Polish case of dysfibrinogenemia, Fi­
brinogen Kraków associated with the Asn325Ile 
mutation in the fibrinogen γ chain and causing 
hypodysfibrinogenemia with thrombotic man­
ifestation, was described in 2009.11 Genetically 
characterized fibrinogens described for the first 
time in Polish patients are shown in TABLE 1 (for 
the whole report, see Wypasek et al12).
Clinical manifestations In patients with afibrino­
genemia, umbilical stump bleeding in newborns 
is the typical first manifestation of the disease, 
observed in 85% of cases.13 Bleeding in afibrino­
genemia may also commonly occur as nosebleeds 
and less frequently cutaneous bleeding, gastro­
intestinal hemorrhage, and genitourinary bleed­
ing. Intracranial bleeding, often spontaneous, is 
the most common cause of death in patients with 
afibrinogenemia.13 Intramuscular and hemarthro­
sis also occur in afibrinogenemia, usually less re­
currently and less damaging than in severe he­
mophilia, even though severe arthropathies have 
also been reported in afibrinogenemia.5 Three ad­
ditional manifestations are considered specific 
for afibrinogenemia, namely spontaneous spleen 
rupture, impaired wound healing, and the forma­
tion of painful bone cysts.14 Afibrinogenemia in 
women is typically associated with spontaneous 
miscarriages in the first trimester of pregnancy.13 
Other pregnancy ­related manifestations include 
pre­ or postpartum hemorrhages, as well as pla­
cental abruption. Indeed, fibrinogen ensures pla­
cental integrity and is necessary for the devel­
opment of blood vessels in its villi.13 Over 50% 
of women with afibrinogenemia have prolonged 
heavy menstrual bleeding that requires hormonal 
treatment.13 Paradoxically, patients with afibrin­
ogenemia may have thromboembolic events as­
sociated with or without fibrinogen substitution 
structure of fibrin, even at lower fibrinogen con­
centrations, could paradoxically increase throm­
botic risk by impairing fibrin degradation by plas­
min or facilitating clot fragmentation.2,3
Congenital fibrinogen disorders Genetic background 
Congenital disorders of fibrinogen is a hetero­
geneous group of rare abnormalities most of­
ten caused by mutations in one of the 3 separate 
genes encoding individual polypeptide chains, 
located on chromosome 4q28 in a cluster of 
about 50 kbp (FGA, FGB, and FGG, respectively, 
for chains Aα, Bβ, and γ, but the order of genes 
from centromere to telomer is as follows: FGB, 
FGA, and FGG).4 So far, over 450 mutations in 
FGA, FGB, and FGG genes have been registered, of 
which over 250 are symptomatic (www.geht.org). 
The most common mutations (50%–80%) are 
single ­amino acid missense mutations. Other 
defects responsible for fibrinogen abnormalities 
include nonsense mutations, read frame changes 
through small deletions or insertions in the cod­
ing part of the gene (frameshift), splicing ­site 
mutations, and large deletions.4 Less than 5% of 
cases are genetic variants located in the 3’ and 
5’ untranslated regions of the genes.5 Still, a few 
patients with severe fibrinogen deficiency have 
no identified genetic cause, and the use of next­
­generation sequencing can help clarify genetic 
background of these disorders.
The causative mutations described so far re­
sult in either qualitative or quantitative fibrino­
gen disorders.4 Quantitative disorders are tradi­
tionally divided into afibrinogenemia (complete 
absence of fibrinogen) and hypofibrinogenemia 
(proportionally reduced functional fibrinogen 
and its antigen levels).4,6 Afibrinogenemia is in­
herited in an autosomal recessive manner, while 
hypofibrinogenemia, dysfibrinogemia, and hy­
podysfibrinogenemia are autosomal dominant.4 
Afibrinogenemia is due to homozygosity or com­
pound heterozygosity of a null mutation.4 It is es­
timated that quantitative congenital fibrinogen 
disorder accounts for 8% of rare coagulation fac­
tor deficiencies.5 The prevalence of afibrinogen­
emia is estimated to be 1/1 000 000 or more in 
some countries where marriage of close relatives 
is common, for example, in Iran.4 As hypofibri­
nogenemias are mainly caused by heterozygosi­
ty for fibrinogen gene mutation, they are much 
more frequent than afibrinogenemia.
Qualitative fibrinogen disorders include dys­
fibrinogenemia (normal amount of dysfunction­
al fibrinogen) and hypodysfibrinogenemia (de­
creased amount of dysfunctional fibrinogen). 
Almost all dysfibrinogenemias are caused by 
heterozygous missense mutations in FGA and 
FGG genes. Their prevalence is unknown as they 
are often asymptomatic.6 In a recent systemat­
ic analysis of exome / genome data from about 
140 000 individuals of genome databases, it was 
estimated that their prevalence is up to 0.3% to 
1%.7 Two hotspot mutations are particularly fre­
quent, one affecting residue Arg35 in exon 2 of 
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and thrombosis was 6 and 13.5 per 1000 adult 
patient ­years, respectively.8 About 25% of pa­
tients with dysfibrinogenemia reported a mild 
bleeding tendency.8,13 Pregnant women with dys­
fibrinogenemia can experience recurrent spon­
taneous miscarriages in the first trimester of 
pregnancy, placenta abruption, and postpartum 
thrombosis.13 In a large patient cohort, approx­
imately 20% of women experienced postpar­
tum hemorrhage, and the risk was 6 ­fold higher 
in women with previous bleeding phenotype.14 
In about 20% of cases, there is a tendency for 
venous and / or arterial thrombosis. The most 
classic example is the Dusart Fibrinogen, due 
to a single base change (C>T) in the Aα ­chain 
gene, resulting in the amino acid substitution 
Aα 554 Arg>Cys and consequently to the for­
mation of very thin fibrin fibers with defective 
plasminogen binding.15 Dysfibrinogemia is a rare 
cause of inherited thrombophilia (about 0.8%)16 
as compared with deficiencies of natural anti­
coagulants, but it cannot be ignored.17,18 There 
is evidence that dysfibrinogenemia can lead to 
a rare severe complication of pulmonary embo­
lism such as thromboembolic pulmonary hy­
pertension.19 Therefore, an extensive fibrino­
gen work up is suggested by experts in patients 
with this type of pulmonary hypertension.14,20 
Prothrombotic mechanisms in dysfibrinogen­
emia may include reduced binding of thrombin 
to the abnormal fibrin network, abnormalities 
in fibrin polymerization with the formation of 
abnormal clot with tendency to fiber fragmenta­
tion and impaired fibrinolysis.13,21 A correlation 
treatment. Deep vein thrombosis and ischemic 
stroke are frequent, but thromboses at unusu­
al arterial and / or venous sites have also been 
reported.4,6,13,15
Hypofibrinogenemia is often asymptomatic 
and diagnosed accidentally, especially when fibrin­
ogen levels are higher than 1 g/l.6 In the remain­
ing patients, the bleeding phenotype predomi­
nates, depending on the fibrinogen level. Spon­
taneous bleeding events, such as heavy periods, 
muscle hematomas, or gastrointestinal bleeding, 
occur in approximately 20% of patients with hy­
pofibrinogenemia, especially when plasma fibrin­
ogen concentrations do not exceed 0.5 g/l.13 Hy­
pofibrinogenemias are also associated with an in­
creased risk of bleeding related to pregnancy, trau­
ma, or surgery.6 It should be noted that in rare 
subtypes of hypofibrinogenemia, fibrinogen ag­
gregates may accumulate in the endoplasmic re­
ticulum of hepatocytes, leading to liver storage 
disease of varying severity.13
Qualitative fibrinogen abnormalities are re­
lated to the reduced activity of normal amount 
of fibrinogen.8,10 Clinical manifestations are 
heterogeneous. Approximately 55% of patients 
are asymptomatic, and about 50% to 60% of 
patients are diagnosed as part of work up due 
to prolonged routine clotting times or reduced 
functional fibrinogen levels, for example, be­
fore invasive procedures or during hospitaliza­
tion.6 Remaining patients can present a bleed­
ing or / and a thrombotic phenotype. In a large 
cohort of patients with a median follow ­up of 
6 years, the overall incidence of major bleeding 
TABLE 1 Congenital fibrinogen disorders genetically characterized for the first time in Polish patients
Fibrinogen ISTH 
classification
Gene Mutation Sex; age at 
diagnosis, y
Functional 
fibrinogen / 
fibrinogen 
antigen, g/l
TT, s Clinical symptoms Bleeding / 
thrombosis 
in family
Belchatow 2B, moderate 
hypofibrino-
genemia
FGG IVS1+5 
G>C, 
c.78+G>C
Woman; 33 0.94/1.2 31.8 2 postpartum 
hemorrhages, 
2 miscarriages
Yes
Cracow 4C, mild 
hypodysfibrino-
genemia
FGG c.1052A>T, 
p.Asn325Ile
Woman; 21 0.62/1.16 21.5 Accidental diagnosis 
during the first 
pregnancy; at age of 16 
years, appendectomy 
complicated by DVT
Yes
Cracow III 3A, dysfibryno-
genemia
FGG c.124G>A, 
p.Gly16Ser
Woman; 44 2.1/2.29 22.5 Bleeding after delivery 
and tooth extraction
No
Poznan 2C, mild 
hypofibrino-
genemia
FGG c.331 A>T, 
p.Lys111X
Man; 25 1.0/1.12 21.1 32 -hour bleeding after 
tooth extraction, 
bleeding from minor 
wounds and nose, easy 
bruising
Yes
Poznan II 3A, dysfibrino-
genemia
FGG del 177bp Woman; 47 1.81/2.6 19.1 Spontaneous miscarriage 
at 33 years complicated 
by vaginal bleeding, 
prolonged menstrual 
bleeding, easy bruising
Yes
Zakopane 2B, moderate 
hypofibrino-
genemia
FGG IVS2 –2 A>C, 
c.124 –
2A>C
Male; 23 0.93/1.2 26.3 Detected accidentally Yes
Abbreviations: DVT, deep vein thrombosis; TT, thrombin time
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disease), confirmed by histological examination 
(2D subtype)
Patients with dysfibrinogenemia (type 3 con­
genital disorder) are distinguished by:
1 Asymptomatic dysfibrinogenemia or dysfi­
brinogenemia with bleeding tendencies or occa­
sional thrombosis (subtype 3A), for which there 
is no clear association with the genotype
2 Dysfibrinogenemia associated with throm­
bosis (subtype 3B) found in patients carrying 
a known mutation increasing the risk of thrombo­
sis (Fibrinogen Dusart, Caracas V, Ijmuiden, New 
York I, Nijmegen, Melun, and Naples in a homo­
zygous form) or in patients with venous throm­
bosis or at an early age with a positive family his­
tory of thrombosis in first ­degree relatives (of 
the same genotype) with no other known cause 
of thrombophilia.
The last group of congenital fibrinogen disor­
ders (type 4) includes patients with hypodysfi­
brinogenemia classified as:
1 Severe hypodysfibrinogenemia with fibrin­
ogen antigen of less than 0.5 g/l (subtype 4A)
2 Moderate hypodysfibrinogenemia with fibrin­
ogen antigen levels between 0.5 and 0.9 g/l (sub­
type 4B)
3 Mild hypodysfibrinogenemia with fibrino­
gen antigen levels from 1.0 g/l to a lower limit of 
the reference range (subtype 4C)
This recent classification22 did not include pa­
tients with an inherited fibrinogen Aα ­chain mu­
tation that causes amyloidosis and fibrinogen 
chain deposition in the kidneys because this fi­
brinogen variant does not affect routine coagu­
lation screening tests.23
Regardless of the type of the fibrinogen muta­
tion found, it is important to note in all patients: 
age at diagnosis; the circumstances in which 
the disease was diagnosed; similar abnormali­
ties or symptoms in the family; and the type of 
clinical manifestation (hemorrhagic, with major 
life ­threatening bleeding, with recurrent throm­
boembolic events, or with the need for fibrino­
gen concentrates).18
Diagnostic work up of congenital fibrinogen disor-
ders Diagnosis of congenital fibrinogen disor­
ders is difficult due to the availability of a vast 
range of analytical methods and reagents to as­
sess the function of blood coagulation and a large 
number of mutations in the 3 fibrinogen genes 
leading to different protein concentrations.4,16 
Traditionally, fibrinogen is the only coagulation 
factor whose potency is expressed in units of 
concentration (most commonly in clinical prac­
tice as g/l), rather than in activity units like oth­
er coagulation factors. The measurements of fi­
brinogen concentrations are standardized. De­
creased fibrinogen concentrations should lead 
to a suspicion of congenital fibrinogen disorders 
and a further diagnostic evaluation should be per­
formed. Of note, a concentration of fibrinogen, 
as an acute phase protein, increases in response 
to inflammatory diseases, infections, nephrotic 
between genotype and phenotype is best docu­
mented for some dysfibrinogenemias, including 
thrombotic ­related variants (described below).5
Hypodysfibrinogenemia is the most rarely re­
ported congenital disorder of fibrinogen. It is as­
sociated with symptoms characteristic of both 
hypofibrinogenemia and dysfibrinogenemia.10 
In case of a discrepancy between reduced activ­
ity and reduced antigen fibrinogen levels, hypo­
dysfibrinogenemia should be suspected.8,10 Post­
partum hemorrhage and heavy menstrual bleed­
ings are particularly frequent, which is why this 
subtype of anomaly is most often described in 
symptomatic women.10,13 The largest literature re­
view published so far, reporting 51 patients diag­
nosed with hypodysfibrinogenemia, showed that 
the cutoff of 0.7 for the ratio of functional concen­
tration of fibrinogen to its antigen level has a di­
agnostic sensitivity of 86%.10 Interestingly, 22% 
of patients with hypodysfibrinogenemia did not 
show clinical manifestations at diagnosis, while 
45% experienced at least 1 benign hemorrhagic 
event prior to diagnosis, 30% of of bleedings oc­
curred during pregnancy, puerperium, and men­
strual disorders.10 Overall, 43% of patients in 
the studied cohort had at least 1 thromboembol­
ic event with a predominance of venous throm­
bosis over arterial thrombosis (3:1).10 Spontane­
ous bleeding associated with fibrinogen abnor­
malities usually occurs at functional fibrinogen 
levels of less than 0.7 g/l.9
Classification of congenital fibrinogen disorders 
The latest recommendations of the Research Stan­
dardization Committee at the International Soci­
ety on Thrombosis and Haemostasis (ISTH) pub­
lished in 2018 introduced a new classification 
of fibrinogen disorders and a modified diagnos­
tic approach to patients with such a suspicion.22 
It has been suggested to classify congenital dis­
orders in fibrinogen based on the clinical and bi­
ological (fibrinogen activity, antigen, and geno­
type) phenotype.22
Afibrinogenemia (type 1 congenital fibrino­
gen disorder):
1 Asymptomatic or bleeding patients are clas­
sified as afibrinogenemia (subtype 1A).
2 Patients with concomitant thromboembol­
ic events are classified as afibrinogenemia with 
phenotypic thrombosis (subtype 1B), even if ac­
companied by hemorrhagic episodes.
Type 2 includes patients with hypofibrinogen­
emia classified as:
1 Severe hypofibrinogenemia with a function­
al fibrinogen concentration of less than 0.5 g/l 
(subtype 2A)
2 Moderate hypofibrinogenemia with a func­
tional fibrinogen concentration of 0.5 to 0.9 g/l 
(subtype 2B)
3 Mild hypofibrinogenemia with a functional fi­
brinogen concentration from 1.0 g/l to the lower 
limit of the reference range (2C subtype)
4 Familial hypofibrinogenemia with accumula­
tion of fibrinogen in the liver (fibrinogen storage 
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TT and reptilase time in the presence of con­
genital fibrinogen disorders are often prolonged, 
but according to the current ISTH guidelines22 
they should be considered only as additional tests 
in patients due to the limited diagnostic value. 
Indeed, even though TT is commonly used by 
hematologists as a dysfibrinogenemia screen­
ing test, results  in the reference range (with pro­
longed reptilase time), as well as prolonged TT, 
still require measurement of functional fibrino­
gen and its antigen level.
Regardless of the diagnostic algorithm, in or­
der to establish the definitive diagnosis of in­
herited fibrinogen disorders, a detailed analy­
sis of the genes encoding individual fibrinogen 
chains is necessary. Screening for these abnor­
malities should be performed in relatives along 
with the assessment of the relationship between 
the genotype and the clinical phenotype.22 It is 
recommended that in quantitative fibrinogen dis­
orders, genetic analysis should start by sequenc­
ing FGA gene (exon 4 and 5), because they often 
contain mutations associated with protein func­
tion loss.29 The next step should be the analysis 
of less commonly mutated exons (FGA, exon 2; 
FGB, exons 2 and 6; and FGG, exons 6 and 8) 
and, if necessary, sequencing of the remaining 
exons.29 In dysfibrinogenemia, the first stage of 
the diagnostic work up should be the screening 
of exon 2 of the FGA gene and exon 8 of the FGG 
gene.29 Next, exon 5 in FGA, exon 2 in FGB, and 
exons 3 and 5 in FGG should be assessed.29 How­
ever, nowadays, the next ­generation sequenc­
ing (eg, whole­exome sequencing) is being more 
cost ­effective in identifying a causative muta­
tion in a rare disease. Standard polymerase chain 
reaction and Sanger sequencing are still useful 
to confirm the molecular anomaly or for famil­
ial studies.
Management of bleeding in congenital fibrinogen 
disorders Treatment of a­ or hypofibrinogen­
emia and sometimes dysfibrinogenemia is to pro­
vide adequate concentrations of functional fi­
brinogen for proper hemostasis by using freshly 
frozen plasma (FFP), cryoprecipitate, or plasma­
­derived fibrinogen concentrate, with the last be­
ing the best option.5,14 Cryoprecipitate and FFP 
are associated with infusion ­related adverse re­
actions, including the risk of fluid overload and 
transfusion ­related acute lung injury as a poten­
tially fatal adverse event.30 In addition, the use 
of FFP and cryoprecipitate is associated with 
the supply of large amounts of other proteins 
such as fibronectin, von Willebrand factor, fac­
tor VIII, factor XIII, and macroglobulin.30 Final­
ly, both require thawing, which delays the infu­
sion of the first dose. Clinical studies have shown 
that the risk of transmitting a pathogen by ad­
ministering fibrinogen concentrate is negligible.30 
Fibrinogen concentrate infusion can be compli­
cated by allergic reactions. The formation of an­
tibodies against this protein have been reported, 
but without inhibitory effects.31
syndrome, during pregnancy, during the use of 
oral hormonal contraceptives, or after surgi­
cal interventions, making diagnosis even more 
challenging and sometimes requiring repeated 
measurements.1,4
Coagulation tests most commonly used in 
the diagnostic work up of congenital fibrinogen 
disorders include: 1) prothrombin time (PT), also 
automatically expressed in most laboratories as 
international normalized ratio (INR); 2) activat­
ed partial thromboplastin time (APTT); 3) throm­
bin time (TT); 4) assessment of fibrinogen con­
centration by the von Clauss method.24
Even a single measurement indicating plas­
ma fibrinogen concentration of less than1.5 g/l 
should lead to a more extensive diagnostic work­
up and, if necessary, genetic testing. The TT assay, 
which is poorly standardized, has the highest di­
agnostic sensitivity, although, similarly to PT and 
APTT, the TT assay has low specificity.25 The mea­
surement of PT, APTT, functional concentration 
of fibrinogen, and the level of its antigen should 
constitute the first stage of diagnostic work up in 
a patient suspected of congenital fibrinogen dis­
orders.22 Determination of the functional concen­
tration of fibrinogen by the von Clauss method 
is based on the measurement of the coagulation 
time of poor platelet plasma (by mechanical or 
optical methods) after activation with high con­
centration thrombin.26 Antigen levels are usually 
measured using specific antibodies with detection 
by immunodiffusion techniques, immunonephe­
lometry, or immunoturbidimetry.26
If the measurement of fibrinogen antigen is 
not available in a given laboratory, the method of 
choice should be the determination of fibrinogen 
concentration based on PT (PT ­derived fibrino­
gen assay).26 PT ­derived fibrinogen is an indirect 
measurement in which the concentration of func­
tional fibrinogen can be estimated on the basis of 
changes in the optical density of plasma, where 
the difference in optical density is proportion­
al to the concentration of fibrinogen compared 
with subsequent dilutions of the standard with 
known concentration of this protein.26 Compared 
with the von Clauss assay, this method is sensi­
tive to changes in plasma optical density associ­
ated with slower fibrinopeptide release and for­
mation of thicker fibrin fibers.26 Therefore, in pa­
tients with dysfibrinogenemia, the PT ­based mea­
surement of fibrinogen concentrations overesti­
mates its actual concentration 5 ­fold compared 
with the von Clauss assay and thus correlates with 
protein levels measured by immunological meth­
ods.26 It is a common practice to use a cutoff of 
less than 0.7 for the ratio of fibrinogen measured 
by the von Clauss assay and the antigen or the PT­
­based method in the diagnosis of dysfibrinogen­
emia.19 It should be noted that some variants, for 
example, fibrinogen Longmont (FGB Arg166Cys) 
or fibrinogen Bordeaux (FGA Arg439Cys), have 
an apparent decrease in fibrinogen concentration 
measured using the PT ­based method compared 
with the von Clauss assay.22,27,28
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of fibrinogen concentrate with a close monitoring 
of peak and trough fibrinogen levels.34 In wom­
en with dysfibrinogenemia and history of recur­
rent miscarriages, fibrinogen supplementation 
could be considered to achieve a functional con­
centration of fibrinogen of around 1 g/l.30 How­
ever, such a strategy does not guarantee favor­
able outcomes and the risk of miscarriage, espe­
cially in the first trimester of pregnancy, remains 
significant.30 There are no data showing that he­
mostasis is still defective after normalization of 
fibrinogen concentration in dysfibrinogenemia. 
Postpartum hemorrhage is a frequent complica­
tion in women with congenital fibrinogen dis­
orders and should be monitored closely. An in­
creased postpartum thrombotic risk has been 
reported. An appropriate thromboprophylaxis 
should be considered in selected women follow­
ing childbirth.30
Management of thrombosis Occurrence of throm­
bosis in afibrinogenemia is a clinical conundrum. 
One hypothesis is that the generation of throm­
bin in a hematoma or during surgery or during 
pregnancy, without the antithrombin action of fi­
brin (ie, acting as a trap for circulating thrombin) 
can lead to strong platelet activation and aggrega­
tion stimulated by thrombin and endothelial cell 
injury, which in turn promotes thrombus forma­
tion and thromboembolic events in both the ve­
nous and arterial systems.35 Thrombosis in such 
patients requires simultaneous supplementation 
of fibrinogen and administration of anticoagu­
lants, most often heparins, with close clinical su­
pervision and laboratory monitoring. Oral direct 
thrombin inhibitors and antiplatelet agents, in 
particular vorapaxar, a protease ­activated recep­
tor 1 antagonist, might be considered in afibrino­
genemic patients with recurrent arterial throm­
boses; however, in most countries, these agents 
are unavailable and their safety remains contro­
versial.36 Besides the few thrombotic ­related dys­
fibrinogenemic variants, all dysfibrinogenemias 
can contribute to an increased thrombotic risk. 
Heparins, precisely low ­molecular ­weight hepa­
rins, for example, enoxaparin, are the drugs of 
choice in treatment of thrombosis in such pa­
tients, as vitamin K antagonists cannot be reli­
ably monitored with INR. The chromogenic assay 
of factor X could be used to determine the correct 
INR value on warfarin in patients with dysfibrin­
ogenemia, in whom the INR cannot be accurate­
ly determined due to interference with the fibrin 
endpoint in the INR assays.37 The duration of an­
ticoagulation depends on the type of thrombosis, 
the familial history, and the overall phenotype of 
a patient. In view of this potential thrombotic 
risk, thromboprophylaxis with heparins should 
be administrated in all clinical settings with an in­
creased thrombotic risk,16 in particular during 
pregnancy and postpartum.38
Key points for internists Due to the rarity of con­
genital fibrinogen disorders, internists are often 
The patients who require fibrinogen supple­
mentation should be treated by hematologists 
trained in the management of bleeding disor­
ders. To summarize the key concepts for internal 
medicine specialists, who may encounter such pa­
tients occasionally, it should be highlighted that 
the therapeutic goal based on expert opinions and 
observational studies is to achieve a functional fi­
brinogen concentration (coagulometric method) 
of 1 to 1.5 g/l. The value of 1 g/l is currently con­
sidered the minimal concentration of fibrinogen 
to maintain the asymptomatic state in most pa­
tients, based on publication from the European 
Network of Rare Hemorrhagic Diatheses32; how­
ever, some experts suggest a lower target concen­
tration of fibrinogen, that is, 0.5 to 1 g/l. Fibrino­
gen is administrated either on demand in case of 
acute bleeding or surgery, or as prophylaxis in pa­
tients with afibrinogenemia or severe hypofibrin­
ogenemia to prevent bleeding. Long ­term prophy­
laxis is recommended in patients with afibrino­
genemia and major recurrent bleedings, but such 
strategy can also be considered in primary pro­
phylaxis (ie, before occurrence of first bleeding). 
Usual infusion strategies, according to the type 
of product, are indicated below:
1 On demand: fibrinogen concentrate, 50 to 
100 mg/kg; cryoprecipitate, 15 to 20 ml/kg; FFP, 
15 to 30 ml/kg.5
2 As prophylaxis: fibrinogen concentrate, 30 to 
100 mg/kg of bw every week; cryoprecipitate, 1 
unit 3 times a week or 3 units every 7 to 10 days.5
The final dosage should be adjusted individually 
depending on the frequency of bleedings and their 
severity. Isolated cases of unsatisfactory hemosta­
sis with recurrent bleeding at fibrinogen concen­
trations of more than 1 g/l have been reported.30 
Increased fibrinogen clearance is seen during ma­
jor bleeding, which requires increased fibrinogen 
concentrate dosage with close monitoring. In case 
of acute bleeding, it is recommended to admin­
ister fibrinogen based at least on daily monitor­
ing.30 Tranexamic acid can also be administered 
in the event of minor bleeding or minor surgery 
planned in patients with hypofibrinogenemia or 
dysfibrinogenemia with a bleeding phenotype.14 
In women with heavy menstrual bleeding, espe­
cially with hypofibrinogenemia, hormonal agents 
should be considered in addition to oral tranexam­
ic acid during menstrual bleeding.
Management of pregnant women Pregnancy is 
a high ­risk clinical situation in women with con­
genital fibrinogen disorders, especially in afibrin­
ogenemia. A multidisciplinary approach including 
an obstetrician, hematologist, and anesthetist, 
preferably in a hemophilia center, is of key im­
portance, and such women should be referred to 
a hemophilia center at the first contact with an in­
ternist. In women with afibrinogenemia or severe 
hypofibrinogenemia, fibrinogen infusion should 
be started as soon as possible.33 Increased fibrin­
ogen clearance is observed in the third trimester 
of pregnancy, requiring an increase in the dosage 
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available and cheap determination of plasma fi­
brinogen concentration using a coagulation assay 
should be considered in patients with bleeding in­
cluding persistent minor bleeds and heavy men­
ses, in particular when there is a positive family 
history. Fibrinogen level measurement should be 
also considered in pregnancy complications and 
thrombosis without clear risk factors. A patient 
suspected of having afibrinogenemia, hypofibri­
nogenemia, or dysfibrinogenemia, with lower fi­
brinogen concentrations (without obvious ac­
quired cause, for example, disseminated intra­
vascular coagulation or massive acute thrombo­
sis), should be referred to a specialist hematolo­
gy center for further diagnostic work up including 
genetic evaluation and family counselling. Prop­
er management is effective in most patients who 
manifest bleeding related to fibrinogen disorders, 
therefore search for this abnormality should be 
encouraged. In Poland, like in many lower ­income 
countries, congenital fibrinogen disorders are un­
derdiagnosed and sparsely reported. Efforts to 
change this situation should be started from in­
creased awareness of afibrinogenemia, hypofibri­
nogenemia, or dysfibrinogenemia among gener­
al practitioners and internists.
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